600380 健康元
已收盘 04-15 15:00:00
资讯
新帖
简况
健康元最新公告：控股子公司JP-1366片获临床试验批准
证券之星 · 04-10
健康元最新公告：控股子公司JP-1366片获临床试验批准
健康元(600380.SH)：TSLP单抗新增适应症获得药物临床试验批准通知书
智通财经 · 04-07
健康元(600380.SH)：TSLP单抗新增适应症获得药物临床试验批准通知书
健康元（600380）披露2025年年度报告，4月3日股价下跌1.57%
证券之星 · 04-03
健康元（600380）披露2025年年度报告，4月3日股价下跌1.57%
健康元(600380)3月31日股东户数7.66万户，较上期减少2.47%
证券之星 · 04-01
健康元(600380)3月31日股东户数7.66万户，较上期减少2.47%
健康元(600380.SH)发布2025年度业绩，归母净利润13.36亿元，同比下降3.68%
智通财经 · 03-31
健康元(600380.SH)发布2025年度业绩，归母净利润13.36亿元，同比下降3.68%
每周股票复盘：健康元（600380）获两项药物临床试验批件
证券之星 · 03-29
每周股票复盘：健康元（600380）获两项药物临床试验批件
健康元最新公告：新一代糖皮质激素获得药物临床试验批准通知书
证券之星 · 03-26
健康元最新公告：新一代糖皮质激素获得药物临床试验批准通知书
健康元最新公告：注射用布瑞哌唑微球获临床试验批准
证券之星 · 03-26
健康元最新公告：注射用布瑞哌唑微球获临床试验批准
股市必读：健康元（600380）3月23日收盘跌5.2%，主力净流入601.31万元
证券之星 · 03-24
股市必读：健康元（600380）3月23日收盘跌5.2%，主力净流入601.31万元
每周股票复盘：健康元（600380）为丽珠单抗担保4亿元
证券之星 · 03-08
每周股票复盘：健康元（600380）为丽珠单抗担保4亿元
健康元（600380）披露控股子公司丽珠集团收购越南IMP公司股权获越方批复，3月6日股价上涨2.85%
证券之星 · 03-06
健康元（600380）披露控股子公司丽珠集团收购越南IMP公司股权获越方批复，3月6日股价上涨2.85%
健康元（600380）披露为控股子公司提供担保进展，3月3日股价下跌1.51%
证券之星 · 03-03
健康元（600380）披露为控股子公司提供担保进展，3月3日股价下跌1.51%
健康元（600380）披露为控股子公司提供担保进展情况，2月4日股价上涨1.49%
证券之星 · 02-04
健康元（600380）披露为控股子公司提供担保进展情况，2月4日股价上涨1.49%
健康元药业集团拟使用不超过29亿元闲置自有资金进行委托理财
中金财经 · 01-31
健康元药业集团拟使用不超过29亿元闲置自有资金进行委托理财
健康元（600380）披露使用不超过29亿元闲置自有资金进行委托理财的公告，1月30日股价下跌0.93%
证券之星 · 01-30
健康元（600380）披露使用不超过29亿元闲置自有资金进行委托理财的公告，1月30日股价下跌0.93%
每周股票复盘：健康元（600380）任命张庆雷为公司副总裁
证券之星 · 01-18
每周股票复盘：健康元（600380）任命张庆雷为公司副总裁
健康元药业集团聘任张庆雷为副总裁，强化创新药研发与商业化布局
中金财经 · 01-17
健康元药业集团聘任张庆雷为副总裁，强化创新药研发与商业化布局
健康元(600380.SH)：莱康奇塔单抗注射液被纳入优先审评审批程序
智通财经 · 01-07
健康元(600380.SH)：莱康奇塔单抗注射液被纳入优先审评审批程序
丽珠医药(01513)：健康元拟将毛孩子49%股权转让给心有毛孩
智通财经 · 2025-12-30
丽珠医药(01513)：健康元拟将毛孩子49%股权转让给心有毛孩
每周股票复盘：健康元（600380）NS-041片获抑郁症临床试验批准
证券之星 · 2025-12-28
每周股票复盘：健康元（600380）NS-041片获抑郁症临床试验批准
加载更多
公司概况
公司名称：
健康元药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2001-06-08
主营业务：
健康元药业集团股份有限公司的主营业务是医药产品及保健品研发、生产及销售。公司的主要产品是化学制剂、化学原料药及中间体、中药制剂、诊断试剂及设备、保健食品、生物制品。
发行价格：
24.80
{"stockData":{"symbol":"600380","market":"SH","secType":"STK","nameCN":"健康元","latestPrice":11.35,"timestamp":1776236401000,"preClose":11.02,"halted":0,"volume":23710780,"delay":0,"changeRate":0.0299,"floatShares":1829000000,"shares":1829000000,"eps":0.7022,"marketStatus":"已收盘","change":0.33,"latestTime":"04-15 15:00:00","open":11.12,"high":11.4,"low":11.07,"amount":267000000,"amplitude":0.0299,"askPrice":11.36,"askSize":109,"bidPrice":11.35,"bidSize":118,"shortable":0,"etf":0,"ttmEps":0.7022,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776303000000},"marketStatusCode":5,"adr":0,"adjPreClose":11.02,"symbolType":"stock","openAndCloseTimeList":[[1776216600000,1776223800000],[1776229200000,1776236400000]],"highLimit":12.12,"lowLimit":9.92,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1829453386,"isCdr":false,"pbRate":1.37,"roa":"--","peRate":16.163486,"roe":"9.13%","epsLYR":0.73,"committee":-0.769558,"marketValue":20764000000,"turnoverRate":0.013,"status":0,"floatMarketCap":20764000000},"requestUrl":"/m/hq/s/600380","defaultTab":"news","newsList":[{"id":"2626196517","title":"健康元最新公告：控股子公司JP-1366片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626196517","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626196517?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:49","pubTimestamp":1775814580,"startTime":"0","endTime":"0","summary":"健康元(600380.SH)公告称，公司控股子公司丽珠集团近日收到国家药监局核准签发的《药物临床试验批准通知书》，同意其申报的JP-1366片开展“与适当的抗生素联用以根除幽门螺杆菌”适应症的临床试验。JP-1366片是一款创新钾离子竞争性酸阻滞剂(P-CAB)，此前该药用于治疗反流性食管炎适应症的上市申请已获受理。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000031077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","600380","BK0239","BK0077","BK0114","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625935060","title":"健康元(600380.SH)：TSLP单抗新增适应症获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2625935060","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625935060?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:02","pubTimestamp":1775552567,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健康元(600380.SH)发布公告，近日，公司收到国家药品监督管理局(简称：国家药监局)核准签发的关于公司的TSLP单抗新增“慢性鼻窦炎伴鼻息肉(CRSwNP)”适应症的《药物临床试验批准通知书》。JKN2401注射液(简称：本品)是一款靶向胸腺基质淋巴细胞生成素(TSLP)的创新生物制剂，拟用于呼吸系统及气道炎症相关疾病的治疗。TSLP是上皮源性关键细胞因子之一，位于多条炎症级联反应通路上游，在气道炎症及慢性鼻窦炎伴鼻息肉等疾病的发生和发展过程中发挥重要作用。通过靶向阻断TSLP通路，本品有望从炎症反应上游对疾病进程进行干预，从而改善相关症状并降低疾病复发风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"健康元(600380.SH)：TSLP单抗新增适应症获得药物临床试验批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600380","BK0077","BK0188","BK0028","BK0239","BK0114","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624651537","title":"健康元（600380）披露2025年年度报告，4月3日股价下跌1.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624651537","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624651537?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:08","pubTimestamp":1775210897,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，健康元报收于11.28元，较前一交易日下跌1.57%，最新总市值为206.36亿元。该股当日开盘11.4元，最高11.45元，最低11.25元，成交额达1.59亿元，换手率为0.76%。健康元药业集团股份有限公司于近日披露《2025年年度报告》。公告显示，截至2025年12月31日，母公司报表期末未分配利润为277,578.45万元。2025年公司总资产为35,414,299,308.64元，归属于上市公司股东的净资产为15,179,567,286.42元。经营活动产生的现金流量净额为3,891,842,483.63元，同比增长7.03%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300035081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0046","600380","BK0114","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624059938","title":"健康元(600380)3月31日股东户数7.66万户，较上期减少2.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624059938","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624059938?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:12","pubTimestamp":1775034767,"startTime":"0","endTime":"0","summary":"证券之星消息，近日健康元披露，截至2026年3月31日公司股东户数为7.66万户，较12月31日减少1943.0户，减幅为2.47%。在化学制药行业个股中，健康元股东户数高于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.45万户。从股价来看，2025年12月31日至2026年3月31日，健康元区间跌幅为3.03%，在此期间股东户数减少1943.0户，减幅为2.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100031096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0114","BK0046","BK0077","600380","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623838615","title":"健康元(600380.SH)发布2025年度业绩，归母净利润13.36亿元，同比下降3.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623838615","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623838615?lang=zh_cn&edition=full","pubTime":"2026-03-31 18:56","pubTimestamp":1774954568,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健康元 披露2025年年度报告，报告期公司实现营收152.16亿元，同比下降2.58%;归母净利润13.36亿元，同比下降3.68%;扣非净利润13.07亿元，同比下降0.94%;基本每股收益0.73元。报告期，公司实现主营业务收入150.88亿元，较上年同期降低4.03亿元，同比下降2.60%。化学制剂实现营业收入72.86亿元，同比下降5.64%，化学原料药及中间体实现营业收入47.09亿元，同比下降5.76%。中药制剂实现营业收入16.86亿元，同比增长14.47%。诊断试剂及设备实现营业收入6.57亿元，同比下降8.56%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423109.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"健康元(600380.SH)发布2025年度业绩，归母净利润13.36亿元，同比下降3.68%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600380"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623338963","title":"每周股票复盘：健康元（600380）获两项药物临床试验批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2623338963","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623338963?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:22","pubTimestamp":1774725732,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，健康元报收于10.98元，较上周的10.96元上涨0.18%。健康元药业集团股份有限公司控股子公司丽珠医药集团股份有限公司全资子公司珠海市丽珠微球科技有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意注射用布瑞哌唑微球开展用于成人精神分裂症的临床试验。后续仍需开展临床试验，上市存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0077","BK0114","BK0188","BK0239","600380","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622685509","title":"健康元最新公告：新一代糖皮质激素获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622685509","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622685509?lang=zh_cn&edition=full","pubTime":"2026-03-26 18:01","pubTimestamp":1774519288,"startTime":"0","endTime":"0","summary":"健康元(600380.SH)公告称，公司收到国家药监局签发的《药物临床试验批准通知书》，同意其自主研发的新一代吸入用糖皮质激素JKN2404吸入混悬液(化学药品1类)开展用于支气管哮喘的临床试验。该药物为高选择性小分子ICS创新药，具有高局部抗炎效用和低全身毒副作用特征，有望降低传统ICS药物带来的HPA轴抑制及儿童生长迟缓等风险。截至公告日，该项目累计研发投入约2258.39万元。据IQVIA数据，2025年国内ICS类药物终端销售额约46.58亿元。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600033066.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0188","600380","BK0114","BK0046","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622385508","title":"健康元最新公告：注射用布瑞哌唑微球获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2622385508","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622385508?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:59","pubTimestamp":1774519197,"startTime":"0","endTime":"0","summary":"健康元(600380.SH)公告称，公司控股子公司丽珠集团全资子公司珠海市丽珠微球科技有限公司收到国家药监局签发的《药物临床试验批准通知书》，同意其申报的注射用布瑞哌唑微球开展用于成人精神分裂症的临床试验。该药品为化学药品2.2类改良型新药，系长效缓释微球制剂，拟定给药方式为每月一次肌肉注射，旨在提升患者用药依从性、降低复发风险。截至公告日，该药品累计研发投入约752.64万元。目前国内尚无布瑞哌唑长效制剂获批上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600033063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600380","BK0028","BK0114","BK0077","BK0188","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621089909","title":"股市必读：健康元（600380）3月23日收盘跌5.2%，主力净流入601.31万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621089909","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621089909?lang=zh_cn&edition=full","pubTime":"2026-03-24 03:19","pubTimestamp":1774293589,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，健康元报收于10.39元，下跌5.2%，换手率1.16%，成交量21.18万手，成交额2.23亿元。当日关注点来自交易信息汇总：健康元股价连续4日下跌，累计跌幅达6.65%，主力资金前10个交易日累计净流出6268.19万元。交易信息汇总股价提醒3月23日健康元收盘报10.39元，跌5.2%，当日成交2118.08万元。资金流向3月23日主力资金净流入601.31万元，占总成交额2.7%；游资资金净流入938.24万元，占总成交额4.21%；散户资金净流出1539.55万元，占总成交额6.91%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400004154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600380","BK0114","BK0188","BK0028","BK0239","BK0046","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617668732","title":"每周股票复盘：健康元（600380）为丽珠单抗担保4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617668732","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617668732?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:17","pubTimestamp":1772907430,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，健康元报收于11.19元，较上周的11.46元下跌2.36%。本周，健康元3月2日盘中最高价报11.46元。截至公告日，公司对外担保余额为212,437.62万元，占最近一期经审计净资产的14.62%，无逾期担保。本公司为丽珠集团提供反担保，比例为26.84%。因交易触发公开要约收购义务，LIAN SGP拟向IMP全体股东发出收购要约。2025年12月30日，公司再次召开董事会，同意推进要约收购并提交相关申请。近日，LIAN SGP已获得越南国家证券委员会对本次要约收购的批复。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600380","BK0239","BK0114","BK0188","BK0046","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617365106","title":"健康元（600380）披露控股子公司丽珠集团收购越南IMP公司股权获越方批复，3月6日股价上涨2.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617365106","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617365106?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:33","pubTimestamp":1772807597,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，健康元报收于11.19元，较前一交易日上涨2.85%，最新总市值为204.72亿元。健康元药业集团股份有限公司近日发布关于控股子公司丽珠集团拟公开收购越南IMP公司股权的进展公告。公告显示，健康元于2025年5月22日召开董事会，审议通过控股子公司丽珠集团拟通过境外全资附属公司LIAN SGP收购越南上市公司Imexpharm Corporation64.81%股份的议案。因交易触发公开要约收购义务，LIAN SGP拟向IMP全体股东发出收购要约。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600040410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["FVNmain","BK0239","BK0187","BK0028","600380","000513","BK0188","BK0114","BK0046","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616602329","title":"健康元（600380）披露为控股子公司提供担保进展，3月3日股价下跌1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616602329","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616602329?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:41","pubTimestamp":1772548878,"startTime":"0","endTime":"0","summary":"截至2026年3月3日收盘，健康元报收于11.1元，较前一交易日下跌1.51%，最新总市值为203.07亿元。近日，健康元药业集团股份有限公司发布《关于为控股子公司提供担保进展情况的公告》。截至公告日，公司对外担保余额为212,437.62万元，占最近一期经审计净资产的14.62%，无逾期担保。本公司为丽珠集团提供反担保，比例为26.84%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300044621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600380","BK0077","BK0239","BK0114","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608005398","title":"健康元（600380）披露为控股子公司提供担保进展情况，2月4日股价上涨1.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608005398","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608005398?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:50","pubTimestamp":1770216628,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘，健康元报收于11.59元，较前一交易日上涨1.49%，最新总市值为212.03亿元。该股当日开盘11.41元，最高11.6元，最低11.34元，成交额达1.45亿元，换手率为0.69%。近日，健康元药业集团股份有限公司发布《关于为控股子公司提供担保进展情况的公告》。截至公告日，公司对外担保余额为228,478.14万元，占最近一期经审计净资产的15.72%，无逾期担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600380","BK0028","BK0114","BK0077","BK0188","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607078904","title":"健康元药业集团拟使用不超过29亿元闲置自有资金进行委托理财","url":"https://stock-news.laohu8.com/highlight/detail?id=2607078904","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607078904?lang=zh_cn&edition=full","pubTime":"2026-01-31 08:58","pubTimestamp":1769821102,"startTime":"0","endTime":"0","summary":"中访网数据 健康元药业集团股份有限公司于2026年1月30日召开第九届董事会第十六次会议，审议通过了关于使用闲置自有资金进行委托理财的议案。根据决议，为提高资金使用效率，公司及控股子公司拟使用总额不超过人民币29亿元的闲置自有资金开展委托理财业务，该额度在决议生效起12个月内可循环滚动使用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260131/31989079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","600380","BK0028","BK0114","BK0046","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607604432","title":"健康元（600380）披露使用不超过29亿元闲置自有资金进行委托理财的公告，1月30日股价下跌0.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607604432","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607604432?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:45","pubTimestamp":1769784313,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，健康元报收于11.67元，较前一交易日下跌0.93%，最新总市值为213.5亿元。该股当日开盘11.78元，最高11.92元，最低11.63元，成交额达1.85亿元，换手率为0.86%。近日，健康元药业集团股份有限公司发布《关于使用闲置自有资金进行委托理财的公告》。投资额度自董事会审议通过之日起12个月内有效，资金可滚动使用。该事项无需提交股东会审议，不构成关联交易。公司已制定风险控制措施，确保资金安全。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0188","BK0114","BK0239","BK0077","600380"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604919923","title":"每周股票复盘：健康元（600380）任命张庆雷为公司副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919923","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604919923?lang=zh_cn&edition=full","pubTime":"2026-01-18 02:49","pubTimestamp":1768675747,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，健康元报收于11.79元，较上周的11.97元下跌1.5%。本周，健康元1月13日盘中最高价报12.41元。本周关注点公司公告汇总：健康元任命张庆雷为公司副总裁，负责药政法规事务及创新药临床与上市工作。公司公告汇总健康元药业集团股份有限公司于2026年1月16日召开九届董事会十五次会议，审议通过任命张庆雷先生为公司副总裁的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600380","BK0028","BK0114","BK0046","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604729910","title":"健康元药业集团聘任张庆雷为副总裁，强化创新药研发与商业化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2604729910","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604729910?lang=zh_cn&edition=full","pubTime":"2026-01-17 09:37","pubTimestamp":1768613826,"startTime":"0","endTime":"0","summary":"中访网数据 健康元药业集团股份有限公司于2026年1月16日召开第九届董事会第十五次会议，审议并通过了关于高级管理人员聘任的议案。董事会同意任命张庆雷先生为公司副总裁，全面负责公司药政法规事务相关工作，旨在加速公司创新药研发与商业化进程，推动创新药产品管线的临床研究申请和新药上市申请。张庆雷先生的任期自董事会表决通过之日起，至公司第九届董事会任期届满之日止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260117/31950329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0077","BK1161","BK0046","BK0114","159992","BK0239","BK1574","600380","06978","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601879557","title":"健康元(600380.SH)：莱康奇塔单抗注射液被纳入优先审评审批程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2601879557","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601879557?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:41","pubTimestamp":1767778878,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健康元(600380.SH)发布公告，公司控股子公司珠海市丽珠单抗生物技术有限公司(简称：丽珠单抗)的产品莱康奇塔单抗注射液于2025年12月26日被国家药品监督管理局药品审评中心纳入拟优先审评品种公示名单;现公示期满后，根据国家药品监督管理局药品审评中心网站信息公开显示，已纳入优先审评品种名单，正式进入药品上市许可优先审评审批程序。拟定适应症(或功能主治)：本品用于适合接受系统治疗或光疗的中重度斑块状银屑病成人患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0077","BK0188","BK0239","BK0114","BK0046","600380"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595679943","title":"丽珠医药(01513)：健康元拟将毛孩子49%股权转让给心有毛孩","url":"https://stock-news.laohu8.com/highlight/detail?id=2595679943","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595679943?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:58","pubTimestamp":1767092313,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药 发布公告，于2025年12月30日，本公司与健康元、心有毛孩及毛孩子订立增资认购及股权转让协议，心有毛孩同意对毛孩子以现金方式增资认缴人民币1500万元，同时，健康元同意将所持有毛孩子49%的股权转让给心有毛孩。本次交易完成后，心有毛孩将持有毛孩子52.56%的股权，本公司持有的毛孩子股权将从51.00%摊薄至47.44%，健康元将不再持有毛孩子股权，毛孩子不再纳入本公司合并报表范围内。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0114","01513","BK0239","BK0077","BK0046","BK0188","600380","BK1191","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2594024272","title":"每周股票复盘：健康元（600380）NS-041片获抑郁症临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2594024272","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594024272?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:25","pubTimestamp":1766867111,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，健康元报收于11.7元，较上周的11.79元下跌0.76%。本周，健康元12月22日盘中最高价报12.03元。本周关注点公司公告汇总：NS-041片获准开展治疗抑郁症的临床试验公司公告汇总：莱康奇塔单抗注射液上市许可申请已获受理公司公告汇总健康元药业集团股份有限公司控股子公司丽珠集团丽珠制药厂收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意NS-041片新增适应症“治疗抑郁症”开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","600380","BK0077","BK0046","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776283961657,"stockEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.0098},{"period":"3month","weight":-0.0494},{"period":"6month","weight":-0.0589},{"period":"1year","weight":0.1009},{"period":"ytd","weight":-0.0173}],"compareEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":-0.0141},{"period":"3month","weight":-0.0208},{"period":"6month","weight":0.0488},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"健康元药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"76582人(较上一季度减少2.47%)","perCapita":"23888股","listingDate":"2001-06-08","address":"广东省深圳市南山区高新区北区朗山路17号健康元药业集团大厦","registeredCapital":"182945万元","survey":" 健康元药业集团股份有限公司的主营业务是医药产品及保健品研发、生产及销售。公司的主要产品是化学制剂、化学原料药及中间体、中药制剂、诊断试剂及设备、保健食品、生物制品。","listedPrice":24.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"健康元(600380)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供健康元(600380)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"健康元,600380,健康元股票,健康元股票老虎,健康元股票老虎国际,健康元行情,健康元股票行情,健康元股价,健康元股市,健康元股票价格,健康元股票交易,健康元股票购买,健康元股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"健康元(600380)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供健康元(600380)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}